Maravai LifeSciences (MRVI) to Release Quarterly Earnings on Thursday

Maravai LifeSciences (NASDAQ:MRVI) will announce its earnings results after the market closes on Thursday, November 7th. Analysts expect Maravai LifeSciences to post earnings of $0.00 per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Maravai LifeSciences (NASDAQ:MRVI) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.08) earnings per share for the quarter. The company had revenue of $73.40 million during the quarter, compared to the consensus estimate of $71.64 million. Maravai LifeSciences had a negative net margin of 47.41% and a negative return on equity of 4.78%. The firm’s revenue for the quarter was up 6.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.06) earnings per share. On average, analysts expect Maravai LifeSciences to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Maravai LifeSciences Trading Up 1.0 %

NASDAQ MRVI opened at $7.85 on Wednesday. Maravai LifeSciences has a 12 month low of $4.52 and a 12 month high of $11.56. The company has a current ratio of 10.00, a quick ratio of 9.28 and a debt-to-equity ratio of 0.71. The stock has a 50 day moving average of $8.25 and a 200-day moving average of $8.52. The company has a market cap of $1.98 billion, a PE ratio of -7.93 and a beta of 0.02.

Analyst Ratings Changes

A number of research analysts have recently commented on MRVI shares. Royal Bank of Canada reissued an “outperform” rating and issued a $15.00 price objective on shares of Maravai LifeSciences in a research report on Friday, August 16th. The Goldman Sachs Group reduced their price target on Maravai LifeSciences from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Tuesday, October 8th. Wells Fargo & Company initiated coverage on Maravai LifeSciences in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $10.00 price objective on the stock. Morgan Stanley downgraded Maravai LifeSciences from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $11.00 to $10.00 in a research note on Tuesday, August 13th. Finally, UBS Group increased their price target on Maravai LifeSciences from $8.50 to $11.00 and gave the company a “neutral” rating in a research note on Thursday, August 8th. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, Maravai LifeSciences currently has an average rating of “Moderate Buy” and a consensus target price of $10.67.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.